LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 2 | N12 | 72 | hr | 1401 | 3936 | 4095 | 0.9611 | 0.9493 |
| SK-BR-3 | Gefitinib | 0.04 | uM | LJP6 | 3 | N12 | 72 | hr | 1401 | 4223 | 4272 | 0.9885 | 0.9856 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 1 | N11 | 72 | hr | 1401 | 3359 | 4139 | 0.8116 | 0.7498 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 2 | N11 | 72 | hr | 1401 | 3748 | 4095 | 0.9152 | 0.8886 |
| SK-BR-3 | Gefitinib | 0.12 | uM | LJP6 | 3 | N11 | 72 | hr | 1401 | 3601 | 4272 | 0.8429 | 0.7983 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 1 | N10 | 72 | hr | 1401 | 3235 | 4139 | 0.7816 | 0.7082 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 2 | N10 | 72 | hr | 1401 | 2918 | 4095 | 0.7125 | 0.6065 |
| SK-BR-3 | Gefitinib | 0.37 | uM | LJP6 | 3 | N10 | 72 | hr | 1401 | 3128 | 4272 | 0.7322 | 0.6475 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 1 | N09 | 72 | hr | 1401 | 2721 | 4139 | 0.6574 | 0.5291 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 2 | N09 | 72 | hr | 1401 | 2710 | 4095 | 0.6617 | 0.5315 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 3 | N09 | 72 | hr | 1401 | 2795 | 4272 | 0.6542 | 0.5361 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 1 | N08 | 72 | hr | 1401 | 2524 | 4139 | 0.6098 | 0.4573 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 2 | N08 | 72 | hr | 1401 | 2536 | 4095 | 0.6192 | 0.4672 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 3 | N08 | 72 | hr | 1401 | 2738 | 4272 | 0.6409 | 0.5166 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 1 | N07 | 72 | hr | 1401 | 1900 | 4139 | 0.4591 | 0.2150 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 2 | N07 | 72 | hr | 1401 | 1715 | 4095 | 0.4188 | 0.1394 |
| SK-BR-3 | Gefitinib | 10 | uM | LJP6 | 3 | N07 | 72 | hr | 1401 | 1700 | 4272 | 0.3979 | 0.1276 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 1 | N18 | 72 | hr | 1401 | 4496 | 3978 | 1.1301 | 1.1692 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 2 | N18 | 72 | hr | 1401 | 4747 | 4213 | 1.1267 | 1.1560 |
| SK-BR-3 | Nilotinib | 0.04 | uM | LJP5 | 3 | N18 | 72 | hr | 1401 | 4934 | 4545 | 1.0854 | 1.0989 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 1 | N17 | 72 | hr | 1401 | 4192 | 3978 | 1.0536 | 1.0706 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 2 | N17 | 72 | hr | 1401 | 4714 | 4213 | 1.1188 | 1.1466 |
| SK-BR-3 | Nilotinib | 0.12 | uM | LJP5 | 3 | N17 | 72 | hr | 1401 | 5276 | 4545 | 1.1606 | 1.1834 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 1 | N16 | 72 | hr | 1401 | 4529 | 3978 | 1.1383 | 1.1798 |
| SK-BR-3 | Nilotinib | 0.37 | uM | LJP5 | 2 | N16 | 72 | hr | 1401 | 4673 | 4213 | 1.1091 | 1.1348 |